AbbVie (ABBV) Enterprise Value (2012 - 2026)
AbbVie (ABBV) reported Enterprise Value of -$9.3 billion for Q1 2026, down 82.06% year-over-year from -$52.1 billion in Q1 2025, and down 79.23% quarter-over-quarter from -$5.2 billion in Q4 2025.
AbbVie (ABBV) Enterprise Value (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Enterprise Value data on file, last reported at -$9.3 billion in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$9.3 billion, down 82.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$9.3 billion (down 82.06% YoY), and the FY2025 annual result was -$5.2 billion, up 5.46% from the prior year.
- Enterprise Value fell to -$9.3 billion in Q1 2026 per ABBV's latest filing, from -$5.2 billion in the prior quarter.
- Over five years, Enterprise Value peaked at -$5.1 billion in Q1 2025 and troughed at -$18.0 billion in Q1 2024.
- A 5-year average of -$9.2 billion and a median of -$8.7 billion in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value tumbled 169.37% in 2024, then surged 71.52% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$9.2 billion in 2022, then tumbled by 38.96% to -$12.8 billion in 2023, then jumped by 56.84% to -$5.5 billion in 2024, then advanced by 5.46% to -$5.2 billion in 2025, then tumbled by 79.23% to -$9.3 billion in 2026.
- Business Quant data shows ABBV's Enterprise Value at -$9.3 billion in Q1 2026, -$5.2 billion in Q4 2025, and -$5.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | -100.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.35 Bn |
| Dec 31, 2025 | -5.22 Bn |
| Sep 30, 2025 | -5.63 Bn |
| Jun 30, 2025 | -6.42 Bn |
| Mar 31, 2025 | -5.13 Bn |
| Dec 31, 2024 | -5.52 Bn |
| Sep 30, 2024 | -7.25 Bn |
| Jun 30, 2024 | -13.11 Bn |
| Mar 31, 2024 | -18.03 Bn |
| Dec 31, 2023 | -12.78 Bn |
| Sep 30, 2023 | -13.26 Bn |
| Jun 30, 2023 | -8.73 Bn |
| Mar 31, 2023 | -6.69 Bn |
| Dec 31, 2022 | -9.20 Bn |
| Sep 30, 2022 | -11.85 Bn |
| Jun 30, 2022 | -9.93 Bn |
| Mar 31, 2022 | -7.54 Bn |
| Dec 31, 2021 | -9.80 Bn |
| Sep 30, 2021 | -12.22 Bn |
| Jun 30, 2021 | -8.58 Bn |